Arakis asks DrKW to prepare float

Arakis, the venture capital-backed biotech company which yesterday sealed a global licensing deal for one of its drugs, has hired Dresdner Kleinwort Wasserstein to prepare for a flotation.

Novartis, the Swiss pharmaceuticals group, has agreed to pay up to $375m (€292m) plus royalties to two UK biotech firms, Arakis and AIM-listed Vectura, for an exclusive license to develop and market a respiratory drug, AD 237, which is about to begin its final clinical trials.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump